King Pharmaceuticals KG All other lines — Year 2
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearTwo.
The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's all other lines — year 2.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is King Pharmaceuticals's all other lines — year 2?
- King Pharmaceuticals (KG) reported all other lines — year 2 of 32.4% in Q4 2025.
- What does all other lines — year 2 mean?
- This represents the second year of development or maturity for claims within the 'All other lines' segment. It provides insight into the progression of claim payments and reserve adjustments as the underwriting year matures.